NCCN Guidelines® Insights: Prostate cancer, version 1.2023: Featured updates to the NCCN Guidelines Guidelines


Authors: Schaeffer, E. M.; Srinivas, S.; Adra, N.; An, Y.; Barocas, D.; Bitting, R.; Bryce, A.; Chapin, B.; Cheng, H. H.; D'Amico, A. V.; Desai, N.; Dorff, T.; Eastham, J. A.; Farrington, T. A.; Gao, X.; Gupta, S.; Guzzo, T.; Ippolito, J. E.; Kuettel, M. R.; Lang, J. M.; Lotan, T.; McKay, R. R.; Morgan, T.; Netto, G.; Pow-Sang, J. M.; Reiter, R.; Roach, M. 3rd; Robin, T.; Rosenfeld, S.; Shabsigh, A.; Spratt, D.; Teply, B. A.; Tward, J.; Valicenti, R.; Wong, J. K.; Berardi, R. A.; Shead, D. A.; Freedman-Cass, D. A.
Title: NCCN Guidelines® Insights: Prostate cancer, version 1.2023: Featured updates to the NCCN Guidelines
Abstract: The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer. © 2022 Harborside Press. All rights reserved.
Keywords: risk assessment; prostatic neoplasms; prostate tumor; humans; human; male
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 20
Issue: 12
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2022-12-01
Start Page: 1288
End Page: 1298
Language: English
DOI: 10.6004/jnccn.2022.0063
PUBMED: 36509074
PROVIDER: scopus
DOI/URL:
Notes: Article -- DOI is currently broken -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James Eastham
    537 Eastham